CIP
EGRX

Chartwell Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Chartwell Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-173,202
Closed -$8.82M – 445
2021
Q4 		$8.82M Sell
173,202
-3,260
-2% -$169K 0.26% 145
2021
Q3 		$9.84M Sell
176,462
-18,878
-10% -$929K 0.31% 125
2021
Q2 		$8.36M Sell
195,340
-2,063
-1% -$85.1K 0.25% 148
2021
Q1 		$8.24M Buy
197,403
+1,724
+0.9% +$80K 0.25% 154
2020
Q4 		$9.11M Sell
195,679
-2,490
-1% -$116K 0.29% 141
2020
Q3 		$8.42M Sell
198,169
-2,077
-1% -$90.9K 0.31% 129
2020
Q2 		$9.61M Buy
200,246
+8,662
+5% +$432K 0.37% 104
2020
Q1 		$8.81M Buy
191,584
+3,595
+2% +$180K 0.41% 89
2019
Q4 		$11.3M Buy
187,989
+1,300
+0.7% +$77.5K 0.37% 113
2019
Q3 		$10.6M Sell
186,689
-10,070
-5% -$566K 0.35% 112
2019
Q2 		$11M Sell
196,759
-10,025
-5% -$523K 0.36% 110
2019
Q1 		$10.4M Sell
206,784
-9,403
-4% -$418K 0.34% 114
2018
Q4 		$8.71M Buy
216,187
+60,578
+39% +$3.12M 0.31% 108
2018
Q3 		$10.8M Sell
155,609
-3,831
-2% -$290K 0.32% 112
2018
Q2 		$12.1M Buy
+159,440
New +$10M 0.36% 101
2017
Q1 		– Sell
-48,739
Closed -$3.87M – 448
2016
Q4 		$3.87M Buy
+48,739
New +$3.54M 0.13% 226

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Chartwell Investment Partners's EGRX Position: Q1 2022 in Review

Chartwell Investment Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 173,202 shares — an estimated $8.82M sold.

Chartwell Investment Partners first reported a position in EGRX in Q4 2016 and held it in 16 quarters. The position peaked at $12.1M in Q2 2018. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • Chartwell Investment Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 173,202 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $8.82M.
  • Chartwell Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 16 quarters.
  • Chartwell Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $12.1M in Q2 2018.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Chartwell Investment Partners's 13F filing for Q1 2022, filed 26 Apr 2022.